Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Target Raised at Morgan Stanley

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lifted by stock analysts at Morgan Stanley from $20.00 to $22.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley‘s price objective suggests a potential upside of 26.16% from the company’s current price.

RARE has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 6th. Canaccord Genuity Group increased their price target on Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a “neutral” rating for the company in a report on Wednesday. Guggenheim dropped their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Finally, TD Cowen dropped their price target on Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Hold” and an average price target of $33.65.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE traded up $0.81 during midday trading on Wednesday, reaching $17.44. 3,483,973 shares of the stock traded hands, compared to its average volume of 2,852,942. The stock has a market capitalization of $1.72 billion, a PE ratio of -2.99 and a beta of 0.37. Ultragenyx Pharmaceutical has a 12-month low of $12.73 and a 12-month high of $39.89. The business has a 50-day moving average of $16.64 and a two-hundred day moving average of $22.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. The company’s revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.81) earnings per share. Research analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock valued at $127,561 over the last quarter. 5.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $355,746,000. Bank of America Corp DE purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth $38,347,000. Jefferies Financial Group Inc. acquired a new position in Ultragenyx Pharmaceutical during the second quarter valued at $31,040,000. Eagle Health Investments LP acquired a new position in Ultragenyx Pharmaceutical during the second quarter valued at $29,521,000. Finally, Candriam S.C.A. boosted its holdings in Ultragenyx Pharmaceutical by 37.1% in the first quarter. Candriam S.C.A. now owns 1,096,182 shares of the biopharmaceutical company’s stock valued at $22,965,000 after purchasing an additional 296,798 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The company reaffirmed its 2026 revenue and 2027 profitability outlook, and said cost reductions are expected to cut 2027 R&D expenses by at least 50% compared with 2025. Company results and outlook
• Positive Sentiment: Ultragenyx said the FDA approved GENGLYCOS and FAYUVI during the quarter. It also entered agreements to sell two priority review vouchers for a combined $413 million, adding a significant potential source of proceeds. Company results and outlook
• Positive Sentiment: Revenue increased 8.2% year over year to $173 million, while the quarterly loss narrowed to $1.16 per share from $1.81 a year earlier. Third-quarter results
• Neutral Sentiment: Analyst target revisions were mixed: Wells Fargo raised its target from $18 to $19 and kept an equal-weight rating, while Wedbush lowered its target from $25 to $22 and maintained a neutral rating.
• Negative Sentiment: Despite year-over-year improvement, Q3 results missed expectations: the $1.16-per-share loss was wider than analysts’ roughly $1.10 estimate, and $173 million in revenue was below the $182.49 million consensus. Q3 earnings report

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.